CD274 and neoplasm: Although PD-L1 levels on tumor cells and infiltrated myeloid cells are one of the predictive biomarkers for responsiveness to PD-1/PD-L1 blockade (64, 65), tumor PD-L1 level is not always applicable for a prognostic biomarker to the ARNAX therapy.